Coherus Oncology (NASDAQ:CHRS) Releases Earnings Results, Misses Estimates By $0.03 EPS

Posted by Brenda Bartman on Nov 9th, 2026

Coherus Oncology (NASDAQ:CHRS – Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.03), Zacks reports. Coherus Oncology had a negative return on equity of 222.75% and a negative net margin of 259.41%. The business had revenue of $14.27 million during the quarter, compared to the consensus estimate of $15.90 million.

Here are the key takeaways from Coherus Oncology’s conference call:

Coherus is concentrating tagmokitug development on esophageal cancer after seeing early activity with tagmokitug plus LOQTORZI: in nine evaluable second-line patients, confirmed response rate was 33%, with additional unconfirmed responses. The company plans to discuss dose and trial design with the FDA in early 2027, including whether a randomized study could support accelerated approval; the data remain preliminary.
The company is targeting a roughly 30% headcount reduction and expects recurring cost savings of $6 million–$7 million per quarter, lowering the LOQTORZI revenue needed to cover core costs from $30 million–$35 million to $25 million–$30 million per quarter. Most savings are expected within two quarters, while substantially preserving the commercial team.
LOQTORZI sales were $14 million, up 3% sequentially but below the company’s 10%–15% growth target amid slower patient starts in some territories. Coherus expects $54 million–$57 million in 2026 revenue and still projects $15 million in Q4; it cited market share of about 20%–22% and opportunities to displace chemotherapy-only and off-label immunotherapy use.
Coherus ended Q3 with $83.6 million in cash and investments, and reported $34 million of operating cash use. The company disclosed that its cash runway is less than 12 months from the 10-Q filing date, excluding potential cost savings, an earnout payment, or ex-U.S. partnering proceeds.

Coherus Oncology Trading Up 6.2%

Shares of NASDAQ:CHRS opened at $0.82 on Tuesday. The firm has a market capitalization of $126.32 million, a P/E ratio of -0.79 and a beta of 1.03. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.77 and a quick ratio of 1.70. The business’s 50-day moving average is $1.12 and its 200 day moving average is $1.50. Coherus Oncology has a 1 year low of $0.73 and a 1 year high of $2.62.

Analyst Ratings Changes

A number of research firms recently commented on CHRS. HC Wainwright initiated coverage on Coherus Oncology in a report on Thursday, October 29th. They issued a “buy” rating on the stock. Weiss Ratings upgraded shares of Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Coherus Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Get Our Latest Report on CHRS

Coherus Oncology Company Profile

(Get Free Report)

Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.